Cosentyx Intravenous (secukinumab)

Intravenous Cosentyx (secukinumab) is covered only for adults (≥18) with FDA‑approved indications—active psoriatic arthritis, active ankylosing spondylitis, or active non‑radiographic axial spondyloarthritis with objective inflammation—and is not covered for patients <18 or for non‑FDA indications. Coverage requires rheumatologist (or rheumatologist/dermatologist for psoriatic arthritis) prescribing/consultation, documentation of diagnosis (for non‑radiographic axial spondyloarthritis: elevated CRP or MRI sacroiliitis), adherence to weight‑based dosing with a maximum maintenance dose of 300 mg per infusion, initial approval 6 months (renewal 12 months), and reauthorization only after ≥6 months on therapy with documented clinical benefit by objective measures or symptom improvement.

"When requesting Cosentyx (secukinumab) intravenous, the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable saf..."